NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said second-quarter revenues increased 236 percent as R&D spending rose 44 percent and profit increased over 240 percent.
 
Total receipts for the three months ended June 30 increased to $2.4 billion from $714 million year over year. Last year's results reflect Thermo Electron's operations prior to its merger with Fisher Scientific in November. Including both firm's results from last year, second-quarter revenues increased 9 percent year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.